河北医药
河北醫藥
하북의약
HEBEI MEDICAL JOURNAL
2014年
15期
2245-2247
,共3页
王超%邢邯英%王杏%刘敏%张哲
王超%邢邯英%王杏%劉敏%張哲
왕초%형함영%왕행%류민%장철
通心络胶囊%糖尿病视网膜病变%黏附分子%NF-κB通路
通心絡膠囊%糖尿病視網膜病變%黏附分子%NF-κB通路
통심락효낭%당뇨병시망막병변%점부분자%NF-κB통로
Tongxinluo capsule%diabetic retinopathy%adhesion molecules%NF-κB pathway
目的:观察通心络胶囊抑制NF-κB通路抑制糖尿病视网膜病变小鼠黏附分子的作用。方法 KK/Upj-Ay小鼠随机分为模型组、通心络高、中、低(生药4、2、1 g/kg)剂量组,另设C57BL /6小鼠对照组。灌胃给药3个月,测定血-视网膜屏障功能;流式测定血液中细胞间黏附分子-1( ICAM-1)、血管细胞黏附分子-1( VCAM-1)含量;Real Time PCR( qPCR)和 Western blot法测定视网膜ICAM-1、VCAM-1和核因子-κB( NF-κB)表达。结果通心络中、高剂组EB含量比模型组明显下降( P <0.01);通心络中、高剂组血清ICAM-1、VCAM-1含量显著下降( P<0.05);通心络组ICAM-1、VCAM-1 mRNA及蛋白表达均显著下降( P <0.01);通心络中、高组核NF-κB表达显著下降( P <0.05);总NF-κB mRNA及蛋白表达在各组差异无统计学意义( P >0.05)。结论通心络胶囊可抑制NF-κB通路抑制糖尿病视网膜病变小鼠黏附分子,改善糖尿病视网膜病变。
目的:觀察通心絡膠囊抑製NF-κB通路抑製糖尿病視網膜病變小鼠黏附分子的作用。方法 KK/Upj-Ay小鼠隨機分為模型組、通心絡高、中、低(生藥4、2、1 g/kg)劑量組,另設C57BL /6小鼠對照組。灌胃給藥3箇月,測定血-視網膜屏障功能;流式測定血液中細胞間黏附分子-1( ICAM-1)、血管細胞黏附分子-1( VCAM-1)含量;Real Time PCR( qPCR)和 Western blot法測定視網膜ICAM-1、VCAM-1和覈因子-κB( NF-κB)錶達。結果通心絡中、高劑組EB含量比模型組明顯下降( P <0.01);通心絡中、高劑組血清ICAM-1、VCAM-1含量顯著下降( P<0.05);通心絡組ICAM-1、VCAM-1 mRNA及蛋白錶達均顯著下降( P <0.01);通心絡中、高組覈NF-κB錶達顯著下降( P <0.05);總NF-κB mRNA及蛋白錶達在各組差異無統計學意義( P >0.05)。結論通心絡膠囊可抑製NF-κB通路抑製糖尿病視網膜病變小鼠黏附分子,改善糖尿病視網膜病變。
목적:관찰통심락효낭억제NF-κB통로억제당뇨병시망막병변소서점부분자적작용。방법 KK/Upj-Ay소서수궤분위모형조、통심락고、중、저(생약4、2、1 g/kg)제량조,령설C57BL /6소서대조조。관위급약3개월,측정혈-시망막병장공능;류식측정혈액중세포간점부분자-1( ICAM-1)、혈관세포점부분자-1( VCAM-1)함량;Real Time PCR( qPCR)화 Western blot법측정시망막ICAM-1、VCAM-1화핵인자-κB( NF-κB)표체。결과통심락중、고제조EB함량비모형조명현하강( P <0.01);통심락중、고제조혈청ICAM-1、VCAM-1함량현저하강( P<0.05);통심락조ICAM-1、VCAM-1 mRNA급단백표체균현저하강( P <0.01);통심락중、고조핵NF-κB표체현저하강( P <0.05);총NF-κB mRNA급단백표체재각조차이무통계학의의( P >0.05)。결론통심락효낭가억제NF-κB통로억제당뇨병시망막병변소서점부분자,개선당뇨병시망막병변。
Objective To investigate the effect of Tongxinluo capsule on adhesion molecules in mice with diabetic retinopathy through inhibiting NF-κB pathway.Methods KK/Upj-Ay mice were randomly divided into model group , Tongxinluo (low-dose,median-dose,high-dose) groups.C57BL/6 mice were selected as control group .The mice were given Tongxinluo intragastrically for 3 months.Then the retina barrier function was detected ,and contents of ICAM-1,VCAM-1 were determined by flow cytometry.The expression levels of ICAM-1,VCAM-1 and NF-κB in retina were detected by Real Time PCR ( qPCR) and Western Blot .Results The contents of EB in Tongxinluo median-dose and high-dose groups were obviously decreased ( P <0.01 );the serum levels of ICAM-1 and VCAM-1in Tongxinluo median-dose and high-dose groups were significantly decreased ( P <0.05);the expression levels of ICAM-1,VCAM-1 mRNA and protein in Tongxinluo groups were obviously decreased ( P <0.01);expression levels of NF-κB in Tongxinluo median-dose and high-dose groups were obviously decreased ( P <0.05),however,there were no significant differences in the expression levels of total NF-κB mRNA and protein among groups ( P >0.05).Conclusion Tongxinluo capsule can inhibit adhesion molecules in mice with diabetic retinopathy mice through inhibiting NF-κB pathway, as a result ,which can improve diabetic retinopathy .